OABIW
OmniAb, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.39
+0.98%Year over year
Reported trailing growth
- Revenue
- +66.9%
- EBITDA
- +50.3%
- EBIT
- +31.6%
- EPS
- +40.0%
- Free cash flow
- +43.4%
- Operating cash flow
- +43.8%
Forward estimates
Based on analyst estimates
- Revenue
- -42.5%
- EBITDA
- —
- EPS
- -26.0%
Three-year CAGR
- Revenue
- -31.9%
- EBITDA
- +6.9%
- EBIT
- +4.0%
- Net income
- -4.4%
- EPS
- +6.6%
- Free cash flow
- +10.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026